Anke Bio's Affiliate Biosyngen Advances Multiple CAR-T Cell Therapies into Clinical Trials, Files for IPO

ANKEBIO stated on December 13 in the investor interaction platform that Bo sheng ji medicine science and technology (suzhou) co., LTD has successfully developed multiple cell products which have entered the clinical validation stage. Among them, the self-developed CD7-CAR-T cell injection (R&D code: PA3-17 injection) and B7-H3-targeted CAR-T cell injection (R&D code: TAA06 injection) have been approved for China registration clinical trials and received orphan drug designation from the U.S. FDA. Additionally, TAA06 injection has obtained RPD designation. Clinical trials are currently underway.